310 related articles for article (PubMed ID: 20470281)
21. [Effect of fosinopril on the rate of neurohumoral and proinflammatory activation in patients with heart failure].
Berezin AE
Klin Med (Mosk); 2004; 82(9):29-32. PubMed ID: 15540418
[TBL] [Abstract][Full Text] [Related]
22. [The influence of I/D polymorphism of the angiotensin I converting enzyme (ACE) gene and 4G/5G polymorphism of plasminogen activator inhibitor (PAI-1) gene promoter on the haemostatic system in patients with essential hypertension and dyslipidemia].
Nowakowska A
Ann Acad Med Stetin; 2005; 51(1):95-105. PubMed ID: 16496609
[TBL] [Abstract][Full Text] [Related]
23. Effects of atenolol or losartan on fibrinolysis and von Willebrand factor in hypertensive patients with left ventricular hypertrophy.
Boman K; Boman JH; Andersson J; Olofsson M; Dahlöf B
Clin Appl Thromb Hemost; 2010 Apr; 16(2):146-52. PubMed ID: 19825910
[TBL] [Abstract][Full Text] [Related]
24. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition.
van de Wal RM; Plokker HW; Lok DJ; Boomsma F; van der Horst FA; van Veldhuisen DJ; van Gilst WH; Voors AA
Int J Cardiol; 2006 Jan; 106(3):367-72. PubMed ID: 16337046
[TBL] [Abstract][Full Text] [Related]
25. Aldosterone antagonism in addition to angiotensin-converting enzyme inhibitors in heart failure.
Bauersachs J; Fraccarollo D
Minerva Cardioangiol; 2003 Apr; 51(2):155-64. PubMed ID: 12783071
[TBL] [Abstract][Full Text] [Related]
26. Effects of angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension.
Erdem Y; Usalan C; Haznedaroğlu IC; Altun B; Arici M; Yasavul U; Turgan C; Cağlar S
Am J Hypertens; 1999 Nov; 12(11 Pt 1):1071-6. PubMed ID: 10604482
[TBL] [Abstract][Full Text] [Related]
27. ACE inhibition versus angiotensin type 1 receptor antagonism: differential effects on PAI-1 over time.
Brown NJ; Kumar S; Painter CA; Vaughan DE
Hypertension; 2002 Dec; 40(6):859-65. PubMed ID: 12468570
[TBL] [Abstract][Full Text] [Related]
28. Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1.
Brown NJ; Agirbasli MA; Williams GH; Litchfield WR; Vaughan DE
Hypertension; 1998 Dec; 32(6):965-71. PubMed ID: 9856958
[TBL] [Abstract][Full Text] [Related]
29. Addition of spironolactone to dual blockade of renin angiotensin system dramatically reduces severe proteinuria in renal transplant patients: an uncontrolled pilot study at 6 months.
González Monte E; Andrés A; Polanco N; Toribio MJ; Santana R; Gutiérrez Martínez E; González J; Ramírez E; Hernández A; Morales E; Praga M; Morales JM
Transplant Proc; 2010 Oct; 42(8):2899-901. PubMed ID: 20970564
[TBL] [Abstract][Full Text] [Related]
30. Fibrinolysis and insulin sensitivity in imidapril and candesartan (FISIC study) recipients with hypertension.
Fogari R; Zoppi A; Salvadeo SA; Mugellini A; Lazzari P; Santoro T; Derosa G
Hypertens Res; 2011 Apr; 34(4):509-15. PubMed ID: 21179101
[TBL] [Abstract][Full Text] [Related]
31. Angiotensin II type 1 receptor blockers reduce tissue factor activity and plasminogen activator inhibitor type-1 antigen in hypertensive patients: a randomized, double-blind, placebo-controlled study.
Koh KK; Chung WJ; Ahn JY; Han SH; Kang WC; Seo YH; Ahn TH; Choi IS; Shin EK
Atherosclerosis; 2004 Nov; 177(1):155-60. PubMed ID: 15488878
[TBL] [Abstract][Full Text] [Related]
32. Aldosterone: role in edematous disorders, hypertension, chronic renal failure, and metabolic syndrome.
Schrier RW; Masoumi A; Elhassan E
Clin J Am Soc Nephrol; 2010 Jun; 5(6):1132-40. PubMed ID: 20448074
[TBL] [Abstract][Full Text] [Related]
33. Effect of spironolactone on impaired fibrinolysis of hypertensive patients.
Yalcin AI; Dincer M; Aslan V; Gulbas Z
Kidney Blood Press Res; 2002; 25(4):260-4. PubMed ID: 12424430
[TBL] [Abstract][Full Text] [Related]
34. Role of angiotensin II in plasma PAI-1 changes induced by imidapril or candesartan in hypertensive patients with metabolic syndrome.
Fogari R; Zoppi A; Mugellini A; Maffioli P; Lazzari P; Derosa G
Hypertens Res; 2011 Dec; 34(12):1321-6. PubMed ID: 21814211
[TBL] [Abstract][Full Text] [Related]
35. Differing effects of mineralocorticoid receptor-dependent and -independent potassium-sparing diuretics on fibrinolytic balance.
Ma J; Albornoz F; Yu C; Byrne DW; Vaughan DE; Brown NJ
Hypertension; 2005 Aug; 46(2):313-20. PubMed ID: 15998706
[TBL] [Abstract][Full Text] [Related]
36. Effects of a long-term pharmacological interruption of the renin-angiotensin system on the fibrinolytic system in essential hypertension.
Sakata K; Pawlak R; Urano T; Takada A
Pathophysiol Haemost Thromb; 2002; 32(2):67-75. PubMed ID: 12214151
[TBL] [Abstract][Full Text] [Related]
37. Renin-angiotensin-aldosterone system blockade effects on the kidney in the elderly: benefits and limitations.
Turgut F; Balogun RA; Abdel-Rahman EM
Clin J Am Soc Nephrol; 2010 Jul; 5(7):1330-9. PubMed ID: 20498247
[TBL] [Abstract][Full Text] [Related]
38. Differential effects of ACE-inhibition and angiotensin II antagonism on fibrinolysis and insulin sensitivity in hypertensive postmenopausal women.
Fogari R; Zoppi A; Preti P; Fogari E; Malamani G; Mugellini A
Am J Hypertens; 2001 Sep; 14(9 Pt 1):921-6. PubMed ID: 11587159
[TBL] [Abstract][Full Text] [Related]
39. [Chronic effects of spironolactone in conjunction with an angiotensin-converting enzyme inhibitor enalapril on circulating procollagen marker P III NP and vascular resistance in patients with essential hypertension].
Ren YH; Liu YQ; Gai LY; Yang TS; Li TD
Zhonghua Xin Xue Guan Bing Za Zhi; 2006 Jun; 34(6):508-11. PubMed ID: 16842666
[TBL] [Abstract][Full Text] [Related]
40. Effect of the plasminogen-plasmin system on hypertensive renal and cardiac damage.
Knier B; Cordasic N; Klanke B; Heusinger-Ribeiro J; Daniel C; Veelken R; Hartner A; Hilgers KF
J Hypertens; 2011 Aug; 29(8):1602-12. PubMed ID: 21610512
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
